Samsung Pharm (001360) — Capital Reinvestment Ratio

Latest as of June 2022: 0.40x

Samsung Pharm (001360) has a Capital Reinvestment Ratio of 0.40x as of June 2022, meaning it reinvests 0% of its operating cash flow (₩1.59 Billion) in capital expenditures (₩638.30 Million). Check Samsung Pharm tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.40x
Capex / Operating Cash Flow

Operating Cash Flow

₩1.59 Billion
KRW

Capital Expenditures

₩638.30 Million
KRW

Data as of

Jun 2022
Most recent filing

Samsung Pharm Capital Reinvestment Ratio (2017–2017)

This chart tracks Samsung Pharm's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see 001360 cash flow conversion.

Annual Capital Reinvestment Ratio for Samsung Pharm (2017–2017)

Year-by-year Capital Reinvestment Ratio for Samsung Pharm from 2017 to 2017. See 001360 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2017 1.19x ₩5.15 Billion ₩6.11 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow